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Backround: Radiotherapy techniques have evolved rapidly over the last decade with the introduction of Intensity
Modulated RadioTherapy (IMRT) in different forms. It is not clear which of the IMRT techniques is superior in the
treatment of head and neck cancer patients in terms of coverage of the planning target volumes (PTVs), sparing
the organs at risk (OARs), dose to the normal tissue, number of monitor units needed and delivery time.
The present paper aims to compare Step and Shoot (SS) IMRT, Sliding Window (SW) IMRT, RapidArc (RA) planned
with Eclipse, Elekta VMAT planned with SmartArc (SA) and helical TomoHDTM (HT).
Methods: Target volumes and organs at risk (OARs) of five patients with oropharyngeal cancer were delineated on
contrast enhanced CT-scans, then treatment plans were generated on five different IMRT systems. In 32 fractions,
69.12 Gy and 56 Gy were planned to the therapeutic and prophylactic PTVs, respectively. For the PTVs and 26 OARs
ICRU 83 reporting guidelines were followed. Differences in the studied parameters between treatment planning
systems were analysed using repeated measures ANOVA.
Results: Mean Homogeneity Index of PTVtherapeutic is better with HT(.06) followed by SA(.08), RA(.10), SW(.10) and SS
(.11). PTVprophylactic is most homogeneous with RA. Parotid glands prescribed mean doses are only obtained by SA
and HT, 20.6 Gy and 21.7 Gy for the contralateral and 25.6 Gy and 24.1 Gy for the ipsilateral, against 25.6 Gy and
32.0 Gy for RA, 26.4 Gy and 34.6 Gy for SW, and 28.2 Gy and 34.0 Gy for SS. RA uses the least monitor units, HT the
most. Treatment times are 3.05 min for RA, and 5.9 min for SA and HT.
Conclusions: In the treatment of oropharyngeal cancer, we consider rotational IMRT techniques preferable to fixed
gantry techniques due to faster fraction delivery and better sparing of OARs without a higher integral dose. TomoHD
gives most homogeneous target coverage with more sparing of spinal cord, brainstem, parotids and the lower
swallowing apparatus than most of the other systems. Between RA and SA, SA gives a more homogeneous
PTVtherapeutic while sparing the parotids more, but the delivery of RA is twice as fast with less overdose to the PTVelective.
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Radiotherapy techniques have evolved rapidly over the last dec-
ade with the introduction of Intensity-Modulated Radiotherapy
(IMRT) in different forms. The sharp dose fall-off gradient of
IMRT permits the administration of a highly conformal and
more homogeneous dose to the planning target volume (PTV)
compared with conventional and conformal radiotherapy [1].
This allows better sparing of the organs at risk (OARs; e.g. par-
otid glands, submandibular and minor salivary glands, larynx
and swallowing structures such as the constrictor muscles, the
base of tongue, the glottic and supraglottic larynx), leading to a
decrease in acute and late side effects [2-5].
Despite the widespread use of IMRT in the treatment of
head and neck cancer (HNC) there is no level I evidence
of superior anti-tumour efficacy and randomised trials are
rare. Two phase III studies in stage I/II nasopharyngeal
cancer showed a benefit of IMRT in parotid sparing [6,7].
The PARSPORTstudy of Nutting et al. [8] reported a 50% re-
duction in late grade 2 or more xerostomia with IMRT
compared to conventional radiotherapy in patients with oro-
pharyngeal and hypopharyngeal cancer, of whom 77% of stage
III/IV. However, a clear benefit, in terms of local tumour con-
trol or survival, of IMRT over the more classical three-
dimensional conformal radiation therapy has not been observed
so far [9,10]. There are also some concerns about a theoretically
higher risk of induction of secondary cancers by IMRT [11,12].
Meanwhile, static beam IMRT has evolved to rotational
IMRT based on Brahme’s theory of more degrees of
freedom resulting in more conformal dose distributions
[13]. These rotational techniques were introduced into the
clinic without much evidence of their superiority over clas-
sical static beam IMRT [14,15]. There are basically two
major ways to perform rotational radiotherapy: cone beam
(Volumetric rotational IMRT first introduced as Intensity
Modulated Arc therapy (IMAT) by Yu [16], but several al-
ternative approaches have been introduced recently) and fan
beam (also referred to as tomotherapy, serial [17] or helical
[18]). The treatment of locally advanced HNC patients is
technologically challenging and it is not clear which of these
IMRT techniques is superior in terms of coverage of the
PTV, sparing of OARs, dose to the normal tissue, beam-on
time and delivery time. Compared to conventional static
beam IMRT, significantly reduced treatment times and total
number of monitor units have been reported for RapidArc
while maintaining similar dose distributions [19,20].
Bertelsen et al. reported single arc SmartArc in comparison
to Step and shoot IMRT, to be at least equivalent in target
coverage and conformity while using less monitor units
and reducing the beam on time [21]. Van Vulpen et al.
reported Helical Tomotherapy to be superior to step and
shoot IMRT with a sharper dose gradient and a reduction
of the normal tissue complication probability (NTCP) of
the parotid glands [22]. Rao et al. found comparable plan
quality for Elekta’s VMAT(Volumetric Modulated ArcTherapy) planned with SmartArc, Helical Tomotherapy
and fixed field IMRT, with a significant reduction in treat-
ment time with SmartArc at the price of worse sparing of
the parotid glands, spinal cord, and brain stem than Helical
Tomotherapy [23]. Clemente et al. contested these findings
[24]. In complex HNC cases with more than the 4 OARs of
Rao contoured, they found VMAT not to provide any dis-
tinct advantage compared with Helical Tomotherapy.
Oliver’s comparison with RapidArc has shown Helical
Tomotherapy to be superior in dose homogeneity at the ex-
pense of a longer treatment time and a higher integral dose
[25]. Jacob compared treatment plans made in rotational
techniques (10 and 25 mm jaw width Helical Tomotherapy
and ‘2 full arcs’ RapidArc) with sliding-window (SW) IMRT
with leaf widths of 2.5, 5 and 10 mm for nine HNC patients
[26]. He concluded that “Helical Tomotherapy plans
showed steeper dose volume histograms for the PTV and
plans appear to be more conformal and more homogeneous
than SW-IMRT plans for all leaf widths and RapidArc plans.
The RapidArc technique can reduce beam-on time while
maintaining dosimetric quality comparable to that of the
SW-IMRT approach”. However, the prescribed dose was
only 50 Gy. A recent study by Wiezorek and colleagues
compared 7 different ‘machine-treatment planning system’
combinations in a simultaneous integrated boost (SIB) tech-
nique to 65.1 Gy or 60.9 Gy [27]. Sliding Window,
RapidArc and Helical Tomotherapy showed better target
dose homogeneity compared to VMATand Step and Shoot
IMRT. HT Helical Tomotherapy best spared the OARs,
results for the other rotational techniques were variable
with RapidArc doing worst for the parotids (26.5 Gy mean
dose) while being the fastest technique by far.
Most of these studies reported only about a few (the most
‘popular’) OARs and the prescribed doses were not always
challenging. Moreover, none of these studies compared with
the new TomoHD system, nor has RapidArc been
compared with SmartArc in HNC before. The TomoHD™
machine was introduced in the Clinique in 12/2010 by
TomoTherapyW to improve the Hi-ArtW system. It has a
higher maximum gantry speed (12 sec per gantry rotation
instead of 15 sec) and also allows for fixed radiation beams
(H for helical and D for direct).
In this multi-centric planning study, we will compare the
dose distribution in OARs and PTVs obtained with trad-
itional static beam Step and Shoot IMRT of Pinnacle and
Sliding Window IMRT of Eclipse with the rotational IMRT
techniques of RapidArc planned with Eclipse, Elekta VMAT
planned with SmartArc and helical TomoHD using a SIB
technique up to 69.12 Gy.
Material and methods
Material
For five patients with locally advanced oropharyngeal cancer
a contrast-enhanced CT scan with 3 mm slice thickness was
Van Gestel et al. Radiation Oncology 2013, 8:37 Page 3 of 11
http://www.ro-journal.com/content/8/1/37acquired in the treatment position with a custom made
immobilization mask. Patient characteristics are mentioned
in Table 1; examples of individual contours can be found in
Additional file 1. Target volumes (primary tumour volume
and bilateral elective lymph node regions) and OARs
were delineated; all data were sent to the participat-




The gross tumour volume (GTV), the clinical target
volume (CTV) and the nearby organs at risk (OARs)
were delineated on the Pinnacle 8.0 m planning system.
The CTV69Gy (i.e. the CTVtherapeutic) was defined as the
GTV + 1 cm (both for the primary tumour and for
lymph node metastases), taking into account that bone,
cartilages, ligaments and muscles can prevent tumour
spread. The remaining CTV for both the primary
tumour (tissue nearby at risk of direct spread) and the
bilateral elective lymph node areas (delineated according
to Gregoire et al. [28]) were united in the CTV56Gy (i.e.
the CTVprophylactic). The planning target volumes (PTVs)
69 Gy and 56 Gy were defined as the respective CTVs
plus a 3 mm margin with exclusion of the skin. This
skin, defined as a 3 mm thick layer under the patient
surface, was excluded from the PTV in order to avoid
1) optimization problems with the static beam IMRT
systems due to their physical inability to create proper dose
in the build-up zone; and 2) overdose to the skin (the so
called ‘skin flash’) created by the rotational IMRT systems.
The PTV69Gy or ‘PTVtherapeutic’ was created as a separated
volume, i.e. was not included in the PTV56Gy (i.e. the
PTVprophylactic), to bypass HT’s overlap priority system in
which a single voxel can only represent one target volume.
The contoured OARs are listed in Tables 2 and 3. The
shoulder was delineated as the humeral head, including
the glenohumeral joint, up to the acromioclavicular
joint. The top of the lung is defined as the cranial part
of the lung above the aortic arc. OARs lying (almost)
completely in the PTV were not contoured. A planningTable 1 Patient characteristics
Patient Location ICD-O 10 Classification
TNM/AJCC VI
1 Base of tongue R C01 T1N2aM0
2 Tonsil R C09 T2N2cM0
3 Tonsil L C09 T3N2cM0
4 Base of tongue R C01 T3N2cM0
5 Tonsil L C09 T2N1M0
average
Bilat = bilateral; LN + = positive lymph node; R = right; L = left; PTVtotal = PTVtherapeutic
by the Pinnacle treatment planning system.risk volume (PRV) of 3 mm was created around the
spinal cord and around the brainstem.
Planning techniques
For each patient a treatment plan was made in the
institution where a specific form of IMRT was in use:
1. An inverse step and shoot (SS) IMRT plan was made
on a Pinnacle3 8.0 m planning system for an Elekta
SL Beam Modulator with 4 mm leave width. Seven
equidistant 6 MV beams were used (210°-260°-310°-
0°-50°-100°-150°) with a maximum of 80 segments
(range 69–79).
2. A sliding window (SW) IMRT plan was made on
Eclipse, version 8.6.15, for a Varian CLINAC 2100 C/D
linear accelerator with 5 mm leaves in the centre of
the field (40 leaves) and 1 cm leaves at the outer 10 cm
of the field. IMRT treatment planning was performed
using a standard 7 field set-up (220°-300°-340°-20°-60°-
140°-180°). The collimators were individually adapted
to the PTV and the spinal cord. 6 MV photon beams
were used for the anterior fields, while 10 MV photon
beams were used for the posterior fields.
3. A RapidArc (RA) treatment was planned for a Varian
CLINAC 2100 C/D upgraded with on board imaging
(OBI) and RapidArc. The plans were optimized using
the Progressive Resolution Optimizer (PRO) 8.6.15
and calculated with Anisotropic Analytical Algorithm
(AAA 8.6.15). Each plan consisted of two 6 MV 360°
arcs, one clockwise (CW) and one counter clockwise
(CCW) of standard 177 control points each. To
avoid tongue and groove effects and to improve
target coverage and OAR protection, collimator
angles were set to 10° (CCW) and 80° (CW) [29].
4. An Elekta VMAT treatment was planned using the
SmartArc (SA) module in the pre-clinical release v9.0
of Pinnacle3 for an Elekta SL20i linear accelerator
equipped with a standard MLC with 1 cm leaves not
allowing interdigitation. The SA plans were generated
using typically a 6 MV dual arc of 356° with advanced




IV A 2 & 3 R 104 483
IV A 2 bilat & 3 R 233 610
IV A bilat 1,2,3,4 380 955
IV A 1b R & 2 bilat 422 831
III 2 L 146 563
257 688
and PTVprophylactic together; PTV volumes reported in this table are calculated
Table 2 Dose-volume constraints for PTVs and organs at risk
Target/Organ at risk Median absorbed
dose or D50%
Mean absorbed dose ALARA Dnear-min or D98% Dnear-max or D2%
PTV 56 56 Gy V59.9 Gy ≥ 95% of planned absorbed
dose
PTV 69 69.12 Gy ≥ 95% of planned absorbed
dose
≤ 107% of planned absorbed
dose
PRV Spinal cord D2 ≤ 50 Gy
PRV Brainstem ≤ 55 Gy D2 ≤ 59 Gy
Parotid gland
contralateral
≤ 23 Gy Mean D, V27
Parotid gland ipsilateral ≤ 27 Gy Mean D, V27
Submandibular gland ≤ 39 Gy Mean D
Oral mucosa ≤ 27 Gy Mean D, V27
Mandible V60
Soft palate ≤ 27 Gy Mean D, V27
Constrictor muscles ≤ 55 Gy Mean D, V20
Cricopharyngeal muscle ≤ 55 Gy Mean D, V20
Base of tongue ≤ 55 Gy Mean D, V20
Larynx ≤ 40 Gy Mean D, V40
Esophagus superior ≤ 35 Gy Mean D, V35
Top of lung V20
Inner ear Mean D, V45
PTV = planning target volume; PRV = planning risk volume; Vx =% volume receiving x Gy; Dx = dose to x% of the volume; D = dose; ALARA = as low as
reasonable achievable.
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set to 20° to avoid tongue-and-groove effects.
5. A Helical Tomotherapy (HT) plan for a TomoHD
system was planned on the Tomotherapy planning
software version HD1.0 with a maximum of three dose
volume histogram control points per volume. A field
width of 2.5 cm, a maximum modulation factor of 2.8
and a pitch of 0.287 (to avoid the thread effect [30])
were used. The dose distribution for each beamlet was
calculated with a convolution/superposition algorithm.
The optimization process used the least mean square
optimization method to optimize the objective function.Prescription and constraints
A simultaneous integrated boost technique had to be
planned in order to deliver in 32 fractions a dose of
69.12 Gy (2.16 Gy / fraction) to the ‘PTV69Gy’ and a
dose of 56 Gy (1.75 Gy / fraction) to the ‘PTV56Gy’,
respecting the prescription guidelines of the International
Commission on Radiation Units and Measurements
(ICRU) report 83 [31].
The dose to all OARs had to be kept as low as possible
respecting the prescription to the PTVs and the constraints
for the OARs as mentioned in Table 2. Moreover, the
participating centres were encouraged to achieve the lowestdose possible for each OAR, regardless of the prescribed
dose (the ‘as low as reasonable achievable’ or ‘ALARA’
principle).Data analysis and statistics
Reporting
The volume of each structure computed by the different
treatment planning systems (TPS) was compared to look
for possible bias due to the different volume calculation
algorithms of the planning systems.
For the PTVs the homogeneity index (HI, (D2%-D98%)/
D50%), the conformity index (CI, V95%Dprescribed(body)/V95%
Dprescribed(PTV)), the mean dose, the Dnear-min (D98%) and
the Dnear-max (D2%) were analysed. The V59.9Gy of the
PTV56Gy (= 107% of the prescribed dose) was calculated as
a marker for the steepness of the dose gradient towards the
PTV69Gy. For 30 OARs the mean dose and specific critical
doses and volumes were analysed. Organs contoured in less
than three patients (due to overlap with the PTV) were
excluded from analysis. Finally the beam-on time, treatment
time and the number of monitor units were compared.Analysis and statistics
Differences in the studied parameters between treatment
planning systems were analysed using the general linear
Table 3 Mean volumes of PTVs and OARs calculated by the different planning systems (in cubic centimetre)
Pinnacle (SS and SA) Eclipse (SW and RA) Helical tomotherapy (HT)
PTV 69 257.0 254.2 251.2
PTV 56 431.4 425.3 414.5
* PRV Spinal cord 64.0 63.4 61.8
* PRV Brainstem 53.9 52.8 52.8
* Parotid gland contralateral 27.6 26.9 26.7
ipsilateral 26.5 26.0 25.7
* Submandibular contralateral 7.4 7.1 7.2
* Oral mucosa 51.0 49.1 50.1
* Mandible 67.7 65.7 64.0
* Middle pharyngeal constrictor 1.6 1.2 1.5
* Lower pharyngeal constrictor 6.5 6.1 6.4
* Cricopharyngeal muscle 2.3 1.9 2.3
* Oesophagus (cranial part) 5.3 4.9 5.1
* Supraglottic larynx 11.3 10.3 11.0
* Glottic larynx 5.1 4.2 5.0
* Top of lung contralateral 438.0 423.5 432.5
ipsilateral 430.5 415.8 425.1
* Brachial plexus contralateral 12.7 11.2 12.2
ipsilateral 11.5 10.3 11.0
* Inner ear contralateral 2.5 2.1 2.4
ipsilateral 2.2 1.8 2.1
* Brain - PRV brainstem 932.1 914.5 922.2
* Skin near PTV 148.6 145.4 127.7
* Eye contralateral 6.8 6.5 6.6
ipsilateral 6.5 6.2 6.4
* Shoulder contralateral 161.4 162.0 158.5
ipsilateral 154.6 156.7 151.8
* Non specified tissue 6473.8 6373.3 6394.0
Bold =more than 5% difference in volume in comparison with Pinnacle; PTV = planning target volume; PRV = planning risk volume.
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variance (ANOVA). By using a heterogeneous covariance
structure in the repeated measures model, we allowed the
variance to differ across systems. All included variables
were checked for normality. The p-values of group
comparisons were adjusted for multiple testing using the
false discovery rate (FDR) correction. All hypotheses were
tested non-directionally with a p-value of less than 0.05
considered to be significant. All analyses were performed
using SAS 9.2 (SAS Institute Inc., Cary, NC).
Results
Volumes
Due to differences in the calculation algorithms, the
volume of most OARs is smaller when calculated
with HT than when calculated with Pinnacle (the me-
dian of the mean differences of all OARs was −2.3%,range −1.1% to −14.0%). Compared to Pinnacle, calculated
OARs volumes were the smallest with SA’s and RA’s
Eclipse (median of mean differences was −4.4%, range
0.9% to −25.3%, with the largest deviations found in the
small volumes). The mean volume of the PTV69Gy and the
PTV56Gy on Pinnacle was 257 cc (95% CI 83 – 431 cc)
and 431 cc (95% CI 330 – 533 cc), respectively. On HT
and Eclipse these volumes were 2.3% and 3.9%, and 1.2%
and 1.4% smaller, respectively (Table 3).
PTVs
An overview of the mean results and corresponding
p-values for PTV69Gy and PTV56Gy is given in Figure 1.
The corresponding dose volume histograms can be found
in Figure 2.
PTV69Gy: while the D2% and D50% ICRU 83 guidelines
were well respected by all TPS, the D98% guideline was
Figure 1 Mean values of PTVs for the different IMRT planning systems.
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significant lower homogeneity index compared to SA, RA,
SW and SS. The mean Conformity Index was best for RA
and better for SW and SA than for SS and HT.
PTV56Gy: compared to the PTV69Gy, the D50% guideline
was generally less well respected, D98% was only respected
by HT. A statistically significant lower homogeneity index
was created by RA compared to HT, SW, SA and SS. The
Conformity index PTV56Gy was statistically worst for SS.
OARs
Of the 30 defined OARs four (upper pharyngeal con-
strictor, base of tongue, soft palate and ipsilateral subman-
dibular gland) were excluded from the analysis because
they were contoured in less than three patients due to
major overlap with the CTV. For the 26 remaining organs
at risk, an extensive list of mean values and of organ
specific critical doses and volumes is given in Figure 3. For
both parotid glands, for example, only SA and HT fulfilled
the prescribed constraints with mean doses of 20.6 Gy
and 21.7 Gy for the contralateral gland and 25.6 Gy and
24.1 Gy for the ipsilateral gland, respectively, against RA’s
25.6 Gy and 32.0 Gy; SW’s 26.4 Gy and 34.6 Gy; and SS’s
29.1 Gy and 35.6 Gy (for p-values, see Figure 3). The dose
volume histograms of both parotids and the total body
can be found in Figure 4.
Monitor units, beam-on time and treatment time
The results can be found in Table 4.
Discussion
Typically, all the IMRT systems are performing quite
well with the rotational IMRT techniques not onlytreating fast but also seeming able to better spare the
organs at risk without compromising on the target
volume coverage.
However, the results of the small OARs (≤10 cc)
should be interpreted carefully as differences in reported
volume among TPS may cause some bias. These
differences may be due to the calculation algorithm and
resolution of the planning systems as reported by Sheng
et al. [32].
Another concern is the statistical power of a sample size
of only 5 patients (each of them judged with the 5 planning
systems). The power to detect small differences between
systems is low, however, when differences between systems
are large and/or the variability within each system is small,
one is able to pick up these differences. Also the context of
the statistical significances is important. Whenever one
system meets a certain constraint where another system
fails to reach this constraint, the value of the difference is
higher (e.g. parotid glands) than when both systems meet
the constraint (e.g. spinal cord, brainstem, constrictor
muscles). The value of a difference is low whenever this
difference is found for an indices that is not included in
the cost function (brachial plexus, eye).
Looking at the PTVs, the D98% ICRU 83 guidelines
are only respected by HT, the D2% guideline of the
PTV69Gy is respected by all techniques . Based on our
results, the coverage of the PTV69Gy is statistically most
homogeneous with HT, followed by SA. RA, on the
other hand, gives the most homogeneous PTV56Gy and
is most conformal for the PTV69Gy. The trade-off
between the D98% and thus a higher probability of cure
on the one hand, and the prescribed mean doses of the
OARs nearby resulting in a possible lower local toxicity
Figure 2 Dose volume histograms of mean PTV69Gy and mean PTV56Gy.
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boost planning studies particularly difficult. Moreover,
the Conformity Index should be interpreted with caution
as a high Conformity Index can not only be explained by
‘uncontrolled’ hotspots outside the PTV but also by a
high D98%, pushing a bigger part of the dose gradient
outside the PTV.
Although the PTV coverage differences between the
plans are often significant, the authors doubt whether
these rather small differences will have any clinical
impact. The clinical consequences for the OARs, on the
other hand, are likely to be more relevant. As the
differences in mean doses between the compared
systems are quite big for some OARs, the better dose
distributions are likely to result into less toxicity. This is
the case for both parotids and for the (lower part of the)
swallowing apparatus.
Both parotid glands are significantly and probably also
relevantly more spared by SA and HT. Numerous
authors have pointed out the importance of this parotid
sparing in limiting/avoiding late xerostomia as animportant factor in the quality of life of the irradiated
HNC patient [2-8,33,34].
Another interesting finding is the dose to the
swallowing apparatus. Based on our results, the dose to
the lower part (cricopharyngeal muscle and cranial part
of the oesophagus) of the swallowing apparatus is lowest
with HT, SA and SS; while the dose to the glottic larynx
is lowest with HT and to the supraglottic larynx highest
with SS. These organs have been reported to be impor-
tant factors in the development of late dysphagia, aspi-
ration and feeding tube dependency [35]. Swallowing
dysfunction has been reported to affect the quality of life
even more than xerostomia [33]. Moreover, swallowing
dysfunction has become a serious threat since the
intensification of HNC therapy by the concurrent use of
chemotherapy to the radiation or by the use of altered
fractionation schedules [34,36].
A lower maximum dose to the spinal cord and the
brainstem may be particularly of importance as a
substantial number of the patients with locally advanced
HNC may develop a loco-regional recurrence within the
Figure 3 Critical doses and volumes of the different organs at risk for the five planning systems.
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many HNC patients are predisposed to develop a second
primary HNC, from 25% at 5 years to 40% at 10 years
[38,39]. These numbers will only increase when patients
will live longer as result of a better global HNC manage-
ment with surgery, IMRT, chemotherapy and biotherapy.
For these heavily pre-treated patients high dose IMRT,
also in combination with chemotherapy, with or without
prior surgery may be the solely remaining curative
option [40]. And such high dose IMRT will be less diffi-
cult to plan and more efficacious (as higher doses can
more safely be administered) when the previous dose to
the spinal cord and brainstem was lower, resulting in a
higher ‘remaining dose to give’.
Most of the results above are not in agreement with
the data of Clemente and Rao as we do find a benefit of
HT over SA over SS [23,24].
In contrast to other studies [21,25] and the general
opinion, we do not find the rotational techniques to have
a higher integral dose as a price for the better sparing of
OARs out of the high dose zone. Neither the mean dose
to the remaining volume at risk, nor the mean dose to the
‘Body minus PTV’, seems to be higher with the rotational
techniques than with the static beam IMRT techniques. In
regard to the monitor units (MU), RA uses the least MU
and HT by far the most, followed by SW. There has been
much debate about a higher number of MUs causingmore scatter dose and leaf leakage radiation and thus
giving a higher risk of secondary cancers [11,12].
In these technically complicated head and neck
patients RA is clearly the fastest IMRT technique,
followed by SA and HT HD with comparable treatment
times. However, the differences among these rotational
techniques seem to be smaller than the differences
reported by Wiezorek (i.e. 2 arcs RA vs. 2 arcs VMAT
planned with Monaco vs. HT HiArt) [27]. For HT this
may be explained by the new HD version used in this
study as its maximum gantry speed is faster than the
one of the former HiArt system (12 sec / rotation vs
15 sec / rotation). Moreover, all the tested rotational
IMRT techniques are found to be faster than the fixed
gantry IMRT techniques [19,41]. This may be important,
not only for patient comfort but also for tumour control.
Of interest in this respect is the observation by Zheng
et al. showing that, in a nasopharyngeal carcinoma cell
culture experiment, longer fraction delivery times gives
less cell kill, probably due to sub-lethal damage repair
during the irradiation [42]. However, in HT, every
section/slice is treated with high dose rate. It is the sum
of all the consecutive sections/slices that takes time.
Therefore, Shaikh et al. found the ‘temporal dose delivery
pattern’ to be much better for HT than for static beam
IMRT [43]. They estimated an increase in the tumor con-
trol probability (TCP) of 2-3% with HT compared to the
Figure 4 Dose volume histograms of mean values of both parotid glands and total body.
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latter. An additional TCP increase of 2-3% due to the
shorter total treatment time is suggested for all rotational
techniques compared to static beam IMRT. However, only
a few studies suggest a benefit this large.
Finally, one has to realise that in the comparison of
different IMRT delivery systems and planning systems a
lot of variables can influence the results: not only the
different calculation algorithms of the different planning
systems but also the leaves, the beam angles chosen, the





n mean SE mean SE
* Beam on time (minutes) 5 1.87 0.20 3.74 0.2
* Treatment time (minutes) 5 14.01 8.17*
* Monitor Units 5 746 79 1125 59
SE = standard error; * = the irradiation time of one of the sliding window IMRT planstrade-off between target volume’s homogeneity, OAR’s
sparing and treatment time, the experience of the planner,
the time spent on a planning, etc.Conclusion
Despite the limitations of a comparison such as used in
the present study, we consider rotational IMRT tech-
niques preferable to fixed gantry techniques due to faster
fraction delivery times and better sparing of OARs with-






mean SE mean SE mean SE
0 2.50 0.00 4.00 0.00 5.94 0.37
3.05 6.00 5.94
415 18 608 24 5052 322
, representative for all sliding window IMRT plans.
Van Gestel et al. Radiation Oncology 2013, 8:37 Page 10 of 11
http://www.ro-journal.com/content/8/1/37OAR doses are quite large so that we do expect a clinical
benefit for these rotational techniques.
In this first planning report on TomoHD, the HT
system gives the most homogeneous target coverage
with more sparing of the spinal cord, brainstem, parotids
and the lower part swallowing apparatus than most of
the other systems. It also seems to be faster than the
former Tomotherapy HiArt version.
In the comparison between RA and SA, SA gives a
more homogeneous PTVtherapeutic while sparing the
parotids more, but RA is twice as fast with less overdose
to the PTVelective.
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